AFT Pharmaceuticals Limited Analysis

Overview

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

Performance

The following information was extracted from AFT Pharmaceuticals Limited's full year results, released on 21 May 2026:

AFT delivers double digit revenue growth and record earnings

Operating profit of $24.4 million ahead of the guidance range

HIGHLIGHTS

• Full year operating revenue up 22% to $254.7 million (FY25: $208.0 million), driven by double-digit sales growth across all territories

• Product sales and royalties up 21% to $251.6 million (FY25: $207.4 million), supported by growth in Australia (19%), a 66% lift in international and 41% in Asia

• Licensing income of $3.1 million (FY25: $0.7 million), reflecting increasing momentum in out-licensing and milestone activity

• EBITDA of $28.8 million (FY25: $20.9 million) and operating profit of $24.4 million (FY25: $17.6 million) as earnings growth offset significant investment in international business hubs and R&D

• Net profit after tax increased 24% to $14.1 million (FY25: $11.4 million)

• Balance sheet remains strong. Net debt of $38.6 million (FY25: $14.5 million), as the company expanded working capital and acquired existing products in South Africa reflecting continued investment in growth

• Dividend of 2.5 cents per share declared (FY25: 1.8 cents per share), reflecting confidence in the company’s outlook

• Ongoing significant investment with FY27 guidance for increased operating profit of $28 million to $32 million; targeting $300 million plus revenue for FY27

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest locally based pharmaceuticals company, today announces it is targeting revenue in excess of $300 million in FY27 after reporting double digit growth across all its territories in the year to end of March 2026

It also announces FY26 operating profit at a record of $24.4 million and ahead of its guidance range of $20 million - $24 million

AFT Pharmaceuticals Chair David Flacks said: “AFT has delivered another strong result, reflecting the strength of our core Australasian business and the benefits of our increasing geographic and product diversification. “We have continued to invest for long-term value creation - progressing international hubs, executing licensing opportunities, and advancing a portfolio of valuable innovative products that can support our ambition to exceed $300 million sales this financial year.”